Daclizumab is a humanized monoclonal antibody that binds to CD25, a high affinity receptor that is expressed at low levels on resting T cells, which are a type of immune cell, and at high levels on T cells that can become activated in response to autoimmune conditions such as MS.
Daclizumab is currently in clinical development for the treatment of multiple sclerosis (MS).
We have a worldwide strategic development collaboration for daclizumab with Biogen Idec in which we share development costs and commercial rights in MS and in indications other than respiratory and transplant. We wholly own the rights for daclizumab in respiratory and transplant indications, which are not subject to our collaboration agreement with Biogen Idec.
TRU-016, a Small Modular ImmunoPharmaceutical (SMIPTM) protein therapeutic, is a novel CD37-directed therapy for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia, or CLL, as well as certain autoimmune and inflammatory disease indications.
TRU-016 is currently in clinical development for CLL. We are also exploring other cancer and autoimmune indications for this molecule.
We have a worldwide strategic collaboration with Trubion Pharmaceuticals for the joint development, manufacture and commercialization of protein therapeutics directed against the CD37 antigen, including TRU-016.
PDL192 is a humanized monoclonal antibody that binds to the TWEAK (tumor necrosis factor-like weak inducer of apoptosis) receptor (TweakR), a cell surface glycoprotein with homology to the family of tumor necrosis factor (TNF) receptors.
PDL192 appears to have dual mechanisms of action, where binding to the target results in a biological signal detrimental to the cancer cell. In addition, PDL192 may be able to recruit the immune system to mediate antibody-dependent cellular cytotoxicity (ADCC) activity to help destroy the tumor. TweakR appears to be over-expressed in a number of solid tumor indications including pancreatic, colon, lung, renal, breast and head and neck cancers, and ongoing scientific work will help prioritize those tumors for therapeutic testing. In preclinical studies, PDL192 also has been shown to inhibit tumor growth of various models of human cancer in mice.
PDL192 is currently in clinical development for solid tumors. We own the worldwide rights to PDL192.
Please visit our PDL192 publications page to view our most recent data presentations for this program.
For inquiries about our clinical trials, please call our information line at 650 454-1400 or visit the National Institutes of Health website (http://www.clinicaltrials.gov).
Volociximab is a chimeric monoclonal antibody that inhibits the functional activity of a5ß1 integrin, a protein found on activated endothelial cells. Blocking the activity of a5ß1 integrin has been found to prevent angiogenesis, which is the formation of new blood vessels that feed tumors and allow them to grow and metastasize. We believe that volociximab may have potential in treating solid tumors and that its role in angiogenesis may also be applicable in ophthalmic indications.
Volociximab is currently in clinical development for non-small cell lung cancer (NSCLC). In the past, we have conducted studies of volociximab in ovarian cancer, pancreatic cancer, renal cell carcinoma and melanoma. The data from these trials and associated analyses have contributed to our understanding of the mechanism of action and safety profile of volociximab, and we are applying this knowledge to our development program. We plan to continue to evaluate the data from our current study and collaborate with our partner, Biogen Idec, to determine future development plans for this antibody.
We have a worldwide strategic development collaboration for volociximab with Biogen Idec in which we share development costs and commercial rights in all indications. We and Biogen Idec have licensed volociximab for ophthalmic indications to Ophthotech Corporation for various milestones and eventual royalties on potential product sales.
For inquiries about our clinical trials, please call our information line at 650 454-1400 or visit the National Institutes of Health website (http://www.clinicaltrials.gov).
Elotuzumab is a humanized monoclonal antibody that binds to CS1, a cell-surface glycoprotein that is highly expressed on myeloma cells but minimally expressed on normal human cells. Elotuzumab appears to induce anti-tumor effects primarily through antibody-dependent cellular cytotoxicity (ADCC) activity towards myeloma cells.
Preclinical data from our elotuzumab program are suggestive of the antibody’s biologic activity. Our studies to date have shown a reduction of human multiple myeloma xenograft tumors in animal models, and destruction of primary multiple myeloma cells obtained directly from patients. We have conducted extensive analysis of the target for elotuzumab, CS1, which is highly expressed in almost all cases of multiple myeloma independent of stage, cytogenetics or prior therapy.
Elotuzumab is currently in clinical development for multiple myeloma.
We have a worldwide strategic collaboration with Bristol-Myers Squibb Company (BMS) for the joint development, manufacture and commercialization of elotuzumab in multiple myeloma and other potential oncology indications.
